Interferon-γ sensitizes osteosarcoma cells to Fas-induced apoptosis by up-regulating Fas receptors and caspase-8

Pediatric Blood and Cancer

Volumn 43, Issue 7, 2004, Pages 729-736

  Inaba, Hiroto ^a,b   Glibetic, Maria ^a   Buck, Steven ^a   Ravindranath, Yaddanapudi ^a   Kaplan, Joseph ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Apoptosis; Caspase 8; Fas; Interferon ; Osteosarcoma

Indexed keywords

BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 8; CASPASE 8 INHIBITOR; DNA FRAGMENT; FAS ANTIBODY; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; GAMMA INTERFERON;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG SENSITIZATION; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, CD95; APOPTOSIS; CASPASE 3; CASPASE 8; CASPASES; CELL LINE, TUMOR; DRUG SYNERGISM; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; OSTEOSARCOMA; UP-REGULATION;

EID: 9344267172     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20151     Document Type: Article

References (37)

1. Young JL Jr, Miller RW. Incidence of malignant tumors in U.S. children. J Pediatr 1975;86:254-258.
2. Marcove RC, Mike V, Hajek JV, et al. Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases. J Bone Joint Surg Am 1970;52:411-423.
3. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-790.
4. Janinis J, McTiernan A, Driver D, et al. A pilot study of short-course intensive multiagent chemotherapy in metastatic and axial skeletal osteosarcoma. Ann Oncol 2002;13:1935-1944.
5. Rodriguez-Galindo C, Daw NC, Kaste SC, et al. Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. J Pediatr Hematol Oncol 2002;24:250-255.
6. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84.
7. Ozaki T, Flege S, Liljenqvist U, et al. Osteosarcoma of the spine: Experience of the Cooperative Osteosarcoma Study Group. Cancer 2002;94:1069-1077.
8. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169:1747-1756.
9. Trauth BC, Klas C, Peters AM, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-305.
10. Suda T, Takahashi T, Golstein P, et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-1178.
11. Chinnaiyan AM, O'Rourke K, Tewari M, et al. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-512.
12. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-827.
13. Medema JP, Scaffidi C, Kischkel FC, et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). Embo J 1997;16:2794-2804.
14. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. Embo J 1995;14:5579-5588.
15. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37-43.
16. Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Annu Rev Biochem 1998;67:227-264.
17. Strander H. Interferon treatment of human neoplasia. Adv Cancer Res 1986;46:1-265.
18. Weller M, Frei K, Groscurth P, et al. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 1994;94:954-964.
19. Ossina NK, Cannas A, Powers VC, et al. Interferon-γ modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 1997;272:16351-16357.
20. Fulda S, Debatin KM. IFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 2002;21:2295-2308.
21. Inaba H, Komada Y, Li QS, et al. mRNA expression of variant Fas molecules in acute leukemia cells. Am J Hematol 1999;62:150-158.
22. Nicoletti I, Migliorati G, Pagliacci MC, et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-279.
23. Ormerod MG. The study of apoptotic cells by flow cytometry. Leukemia 1998;12:1013-1025.
24. Komada Y, Inaba H, Zhou YW, et al. mRNA expression of Fas receptor (CD95)-associated proteins (Fas-associated phosphatase-1/FAP-1, Fas-associating protein with death domain/FADD, and receptor-interacting protein/RIP) in human leukaemia/lymphoma cell lines. Br J Haematol 1997;99:325-330.
25. Houghton JA, Harwood FG, Gibson AA, et al. The Fas signaling pathway is functional in colon carcinoma cells and induces apoptosis. Clin Cancer Res 1997;3:2205-2209.
26. Bernassola F, Scheuerpflug C, Herr I, et al. Induction of apoptosis by IFNγ in human neuroblastoma cell lines through the CD95/ CD95L autocrine circuit. Cell Death Differ 1999;6:652-660.
27. Arase H, Arase N, Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 1995;181:1235-1238.
28. Fellenberg J, Mau H, Scheuerpflug C, et al. Modulation of resistance to anti-APO-1-induced apoptosis in osteosarcoma cells by cytokines. Int J Cancer 1997;72:536-542.
29. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000;6:529-535.
30. Fulda S, Kufer MU, Meyer E, et al. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001;20:5865-5077.
31. Strander H, Bauer HC, Brosjo O, et al. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol 1995;34:877-880.
32. Kleinerman ES, Jia SF, Griffin J, et al. Phase II study of liposomal muramyl tripeptide in osteosarcoma: The cytokine cascade and monocyte activation following administration. J Clin Oncol 1992;10:1310-1316.
33. Kleinerman ES, Meyers PA, Raymond AK, et al. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: Tolerability, toxicity, and immune stimulation. J Immunother 1995;17:181-193.
34. Worth LL, Jeha SS, Kleinerman ES. Biologic response modifiers in pediatric cancer. Hematol Oncol Clin North Am 2001;15:723-740.
35. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-682.
36. Chaudhary PM, Eby M, Jasmin A, et al. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997;7:821-830.
37. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163.